Dergiler / Turkish Journal of Biology / 2022 / Cilt: 46 - Sayı: 2

Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19

Sayfa
105–117
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Even though further studies are needed to fully understand T cell response against SARS-CoV-2 in order to develop therapies to provide long term and efficient protection, adoptive cell therapies now meet the demand for a large population of people who suffer immunocompromization, considering the previous usage of the technique for different infectious diseases.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Coronavirus disease 2019 (COVID-19) pandemic has been an important global interest that affected millions of people, and it requires a deep investigation of the disease immunology for developing further therapeutic applications.
📊
Temel Bulgular & Veri:Adoptive T cell therapy promises to address T cell-dependent immune dysregulation in COVID-19 patients by the generation of specific T cell clones against virus-specific antigens.
💡
Sonuç & Katkı:Even though further studies are needed to fully understand T cell response against SARS-CoV-2 in order to develop therapies to provide long term and efficient protection, adoptive cell therapies now meet the demand for a large population of people who suffer immunocompromization, considering the previous usage of the technique for different infectious diseases.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Coronavirus disease 2019 (COVID-19) pandemic has been an important global interest that affected millions of people, and it requires a deep investigation of the disease immunology for developing further therapeutic applications. Adoptive T cell therapy promises to address T cell-dependent immune dysregulation in COVID-19 patients by the generation of specific T cell clones against virus-specific antigens. Additionally, targeting B cell-dependent protection through COVID-19 vaccines, which have been developed in the recent year, possessed sufficient prevention for spreading the virus, since the cases and deaths related to COVID-19 tend to decrease after the vaccination. However, adoptive cell therapies are now encouraging scientists to deal with pathological challenges like inadequate T cell-dependent immune response or lymphopenia, since they are the most frequent outcome of severe infection, especially in immunocompromized patients. In this review, the current knowledge of immunopathology of COVID-19 was aimed to be highlighted along with the T cell responses against SARS-CoV-2 to comprise a basis for therapeutics. Moreover, current therapeutics and treatment strategies for COVID-19 were discussed to evaluate possible agents. Furthermore, the use of adoptive T cell therapy representing an emerging therapeutic approach was purposed to be presented comprehensively against SARS-CoV-2 infection. Even though further studies are needed to fully understand T cell response against SARS-CoV-2 in order to develop therapies to provide long term and efficient protection, adoptive cell therapies now meet the demand for a large population of people who suffer immunocompromization, considering the previous usage of the technique for different infectious diseases.

🔖

Bu Makaleye Atıf Yap

TAŞ, S. K., KIRKIK, D., UZUNOĞLU, M. S., UZUNOĞLU, A. S., ALTUNKANAT, D., KALKANLI, N. (2022). Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19. Turkish Journal of Biology, Cilt: 46 - Sayı: 2, 105–117. https://ajindex.com/articles/600092

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Agerer B, Koblischke M, Gudipati V, Montaño-Gutierrez LF, Smyth M et al. (2021). SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses. Science Immunology 6 (57): 6461. doi: 10.1126/SCIIMMUNOL.ABG6461 Altmann DM, Boyton RJ (2020). SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. In Science Immunology American Association for the Advancement of Science 5 (49): 6160. Bachanova V, Bishop MR, Dahi P, Dholaria B, Grupp SA et al. (2020). Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biology of Blood and Marrow Transplantation 26 (7): 1239–1246.
  2. Barker H, Parkkila S (2020). Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2. PLoS ONE 15 (10): e0240647. Basar R, Daher M, Rezvani K (2020). Next-generation cell therapies: the emerging role of CAR-NK cells. Hematology: The American Society of Hematology Education Program 2020 (1): 570. doi: 10.1182/HEMATOLOGY.2020002547 Basar R, Uprety N, Ensley E, Daher M, Klein K et al. (2021). Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. Cell Reports 36 (3): 109432. doi: 10.1016/J.CELREP.2021.109432 Bates TA, Leier HC, Lyski ZL, Goodman JR, Curlin ME et al. (2021). Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples. JAMA doi: 10.1001/JAMA.2021.11656 Bertoletti A, Tan AT (2020). Challenges of CAR- and TCR-T cell– based therapy for chronic infections. Journal of Experimental Medicine 217 (5): e20191663. doi: 10.1084/JEM.20191663 Bertoletti A, Tan AT, Le Bert N (2021). The T-cell response to SARSCoV-2: kinetic and quantitative aspects and the case for their protective role. Oxford Open Immunology 2 (1): iqab006. doi: 10.1093/OXFIMM/IQAB006 Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M et al. (2021). T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Science Translational Medicine 13 (590): 7517. doi: 10.1126/SCITRANSLMED.ABF7517 Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D et al. (2020). Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 181 (5): 1036-1045.e9. Bourgonje AR, Abdulle AE, Timens W, Hillebrands J, Navis GJ et al. (2020). Angiotensin‐converting enzyme 2 (ACE2), SARS‐ CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19). The Journal of Pathology 251 (3): 228–248. Br